Palvella Therapeutics
PVLA
25 hedge funds and large institutions have $10.1M invested in Palvella Therapeutics in 2024 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 7 reducing their positions, and 3 closing their positions.
182% more capital invested
Capital invested by funds: $3.58M → $10.1M (+$6.51M)
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
19% more funds holding
Funds holding: 21 → 25 (+4)
17.37% more ownership
Funds ownership: 28.51% → 45.88% (+17%)
57% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 7
Top Buyers
Top Sellers
PVLA Hedge Fund Activity: Q3 2024 in Review
25 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q3 2024, worth a combined $10.1M — up 182% from $3.58M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new PVLA positions and 3 closed out — a net gain of 4 holders — while 3 added to existing stakes and 7 trimmed.
The largest buyer was ADAR1 Capital Management, opening a new position worth an estimated $2.11M. The largest seller was Acadian Asset Management, cutting an estimated $114K.
- 25 institutional investors held Palvella Therapeutics (PVLA) as of Q3 2024, up from 21 in Q2 2024.
- Funds reported $10.1M of Palvella Therapeutics stock for Q3 2024, up 182% quarter-over-quarter.
- 7 funds opened new Palvella Therapeutics positions in Q3 2024 and 3 closed out, a net change of +4 holders.
- The largest Palvella Therapeutics buyer in Q3 2024 was ADAR1 Capital Management, an estimated $2.11M added.
- The largest Palvella Therapeutics seller in Q3 2024 was Acadian Asset Management, an estimated $114K sold.
Based on aggregated 13F filings for Q3 2024.